Although these in vivo data clearly link znf202 activity to hypoalphalipoproteinemia, the apparent lack of correlation between the in vitro data of us and others and the hepatic gene expression profiles at 5 days after adenoviral Znf202 administration was a surprise. This evidence concerns the gene ZNF202 and hypoalphalipoproteinemia.